CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row

By Sam Reisman · July 18, 2023, 3:58 PM EDT

British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex....

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. et al

Case Number

2:23-cv-00018

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

January 03, 2023